Author: BP Editor
-
Sanofi’s Pipeline Reset Signals a New Era of R&D Discipline
Sanofi’s latest pipeline review highlights a shift from expanding R&D portfolios to making more disciplined investment decisions. Here’s why that matters for the future of big pharma.
-
J&J Takes a Profit Hit to Secure an In Vivo CAR-T Platform
Johnson & Johnson accepted near-term earnings pressure to secure access to Sail Biomedicines’ in vivo CAR-T platform, placing a major bet on scalable cell-therapy delivery.
-
AstraZeneca Keeps Its $80 Billion Goal Despite a Major Trial Setback
AstraZeneca reaffirmed its $80 billion revenue ambition after reporting solid second-quarter results. Strong oncology and rare disease sales helped restore confidence following the failure of a major Wainua trial.
-
Why AstraZeneca Says Drug Development Must Move at “Chinese Speed”
AstraZeneca believes the next pharmaceutical race will be defined not only by scientific innovation, but also by development speed. As competition from Chinese biotech grows, AI could help accelerate drug development and improve efficiency.
-
Why Big Pharma Is Buying Biotech Again: The Patent Cliff Explained
Patent expirations are reshaping the pharmaceutical industry. Here’s why Big Pharma is buying biotech companies again—and what investors should watch next.
-
Can GSK Deliver Its £40 Billion Growth Ambition?
GlaxoSmithKline (GSK) will unveil its long-term growth strategy on July 28. As CEO Luke Miels leads his first major investor event, the focus will be on whether oncology expansion and HIV transformation can realistically support the company’s £40 billion revenue ambition by 2031.
-
Novo Nordisk’s Wegovy Shows Liver-Health Benefits Beyond Weight Loss in MASH Patients
Novo Nordisk’s once-weekly semaglutide 2.4 mg (Wegovy) demonstrated remarkable liver-health improvements in metabolic dysfunction-associated steatohepatitis (MASH) patients—even those with minimal weight loss—signalling a potential paradigm shift in the obesity-related liver-disease market.
-
Eli Lilly Strikes $475 M Gene Therapy Deal with MeiraGTx for Rare Retinal Disease
Eli Lilly’s $475 million acquisition of MeiraGTx marks a bold step into next-generation gene therapies targeting rare retinal diseases. Despite challenges in the gene therapy market, the move reflects growing optimism about using advanced genetic tools to improve the lives of patients with rare inherited disorders.
-
Eli Lilly Advances Obesity Drug Pipeline After Positive Phase 2 Results
Eli Lilly has advanced its novel non-incretin obesity drug into Phase 3 clinical trials after promising Phase 2 results. This move marks a significant milestone in the evolving obesity-treatment landscape, as the company explores mechanisms beyond the incretin pathway. The announcement highlights the growing diversification of obesity therapies and intensifying competition among global pharma leaders.
-
Pfizer Lands Metsera Acquisition After Novo Nordisk Bows Out of $10 B Bidding War
Pfizer’s acquisition of Metsera secures a high-potential obesity-drug pipeline — but because Metsera’s assets are early-stage, the deal carries meaningful regulatory and execution risk.